There is long-term experience with influenza vaccination in pregnant women in Europe and the USA where the safety and efficacy of current inactivated influenza vaccines have been confirmed. Objective: to evaluate the efficiency and safety of Russian inactivated subunit immune adjuvanted influenza vaccine for pregnant women, fetuses, and neonatal development. Subjects and methods. The efficacy of the inactivated subunit immune adjuvanted influenza vaccine Grippol plus was clinically and immunologically evaluated in 50 second- and third-trimester pregnancy women and to investigate the impact of vaccination on the development of fetuses and infants under age 6 months. A placebo group consisted of 41 nulliparae receiving buffer-saline solution (placebo). Results. The vaccination did not cause unusual phenomena or worsen the course of pregnancy. Major biochemical parameters, hormonal status (estradiol, progesterone, prolactin, cortisol), fetoplacental unit markers (α-fetoprotein, human chorionic gonadotropin, trophoblastic β1-glycoprotein), immunoglobulins A, M, G, and E in the observed groups corresponded to those in definite periods during physiological pregnancy. The vaccination was found to have no negative impact on fetal development. Six-month physical and mental development indices were comparable with the babies’ health indices in the placebo group. The incidence of respiratory infections in the infants born to the vaccinated mothers was noted to decrease to 14.6% versus 22.9% in the unvaccinated (p < 0.05). There was evidence that the vaccine was immunogenic in 72% of the pregnant women preserving the protective values for more than 6—9 months. The level of antibodies (≥1:20) to all influenza virus strains was found in 25.6% of the babies 6 months after birth, suggesting that the vaccination in pregnant women is effective in preventing influenza in babies during the first six months of life. Conclusion. The administration of subunit immune adjuvanted influenza vaccine in the second and third trimesters does not affect the physiological course of pregnancy, fetal development, and infant health assessment criteria. There is evidence for the immunogenicity of the vaccine in pregnant women and its specific protection of infants from influenza during 6 months. The authors declare no conflicts of interest.